Camrelizumab plus apatinib for advanced cervical cancer

For women with advanced disease who have received multiple prior lines of treatment for cervical (cervix) cancer, a new combination of the immunotherapy anti-PD-1 antibody camrelizumab and the antiangiogenic (VEGFR inhibitor) apatinib showed positive results in Journal of Clinical Oncology, as reported in the phase II CLAP study.
Immunotherapy plus a targeted drug in cervical cancer
This multicenter study from China included 45 patients whose cancer had progressed after at least 1 prior line of systemic treatment. Patients were enrolled between January and August 2019 and received 200 mg camrelizumab every 2 weeks and 250 mg apatinib once daily in 4-week cycles for a maximum of 24 months. A total of 41 patients with evaluable results were included in the efficacy analysis.
The primary endpoint measured in the study was the objective response rate. A total of 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease, and 67% had PD-L1-positive disease.
Results
- The median follow-up was 11.3 months.
- An objective response was observed in 25 of 45 patients (55.6%), including complete responses in 2 (4.4%). An additional 12 patients (26.7%) had stable disease, yielding a disease control rate of 82.2%.
- An objective response was observed in 25 of the 41 patients (61%) whose efficacy could be evaluated.
- The median duration of response was not reached because more than half of the patients continued to respond to treatment.
- At the time of analysis, 16 of the 25 responses were ongoing, and the response lasted 6 months or longer in 71.5% of these individuals and ≥ 12 months in 66.8%.
- Median progression-free survival was 8.8 months, and the 6-month progression-free survival rate was 57%.
- Although median overall survival was not reached, the 9-month overall survival rate was 69.2%.
- Objective response rates were 69% versus 50% in patients with PD-L1-positive and PD-L1-negative tumors (no statistical difference).
- Objective response rates were 77.8% in 30 patients with squamous cell carcinoma and 28.6% in 15 patients with adenocarcinoma.
Side effects
- Treatment-related grade 3 or 4 (serious) side effects occurred in 71.1% of patients.
- The most common were hypertension (24.4%), anemia (20%), and fatigue (15.6%).
- Serious treatment-related side effects occurred in 4 patients (8.9%): rash in 2 patients; pneumonia in one; and neutropenia, anemia, and thrombocytopenia in one patient. Side effects led to treatment discontinuation in three patients (6.7%). No treatment-related deaths were observed.
- The most common potentially immunotherapy-related side effects were grade 1 or 2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%).
In conclusion Camrelizumab plus apatinib had promising antitumor activity and manageable side effects in patients with advanced cervical cancer. Larger randomized controlled studies will certainly follow to confirm these findings.
*
RELATED TOPIC
The extent to which the HPV vaccine reduces cervical cancer risk has been found
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.